US Patent Issued to The General Hospital on May 27 for "Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants" (Massachusetts Inventors)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,312,613, issued on May 27, was assigned to The General Hospital Corp. (Boston).

"Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants" was invented by Benjamin Kleinstiver (Medford, Mass.) and Russell T. Walton (Waban, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Streptococcus pyogenes Cas9 (SpCas9) variants with relaxed PAM requirements capable of high-resolution editing for various applications, and methods of use thereof."

The patent was filed on Jan. 25, 2021, under Application No. 17/157,708.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?S...